Drug Treatment Outcome Study Navigation


Drug Treatment Outcome Study

|

Partners
Tell A Friend about us
Alcohol Drug Recovery |
Drug Rehab Bainbridge Ga |
Wealden Drug Alcohol Treatment |
Alcohol Treatment Myrtle |
6th Ave Greeley Colorado RtC Drug Rehab |
Alcohol Treatment Lancaster Pa |
California Substance Abuse |
Non Aa Alcohol Treatment |
Alcohol Treatment Nashville Tn |
Drug Rehab Oxycontin |
Free Drug Rehab Kentucky |
Drug Rehab Torrington Ct |
Drug Rehab Athens Georgia |
Alcohol Treatment Brighton |
Drug Treatment Escondido |

List of Drug-Alcohol-Treatment Articles

Drug Treatment Outcome Study Best Seller



Best Drug Treatment Outcome Study Products

Social bookmarking
You like it? Share it!
socialize it


Main Drug Treatment Outcome Study Sponsors


Drug Treatment Outcome Study

 

Latest Drug Treatment Outcome Study Link Added

Top 5 Drug and Alcohol Treatment Pages

1. Drug Rehab
2. Drug Alcohol
3. Drug Treatment
4. Drug Addiction
5. Alcohol Treatment




Submit your link on Drug Treatment Outcome Study!


Welcome to Drug and Alcohol Treatment


 

Drug Treatment Outcome Study Article

Thumbnail example

This is a selection made from among articles on Drug Treatment Outcome Study. For a permanent link to this article, or to bookmark it for future reading, click here.

from: Drug and Alcohol Rehab




Drug and Alcohol Rehab
By Ken Marlborough




Rehabilitation from drug addiction is a complex process. It involves commitment from the individual addict to abstain from further drug use. The physical dependence on the drug needs to be overcome through medical intervention. Medical supervision is essential to safely detoxify an addicted individual. Safety is an issue since sudden withdrawal of a drug will lead to very profound physiological changes that can be very uncomfortable and can sometimes be life threatening. The range of drugs abused is wide but general principles apply to drug and alcohol rehabilitation.



After the medical detoxification process, which is often in an inpatient setting, a program to continue the rehab process as an outpatient is essential. Sometimes replacement drugs are needed such as methadone maintenance programs where patients are given methadone to replace the heroin that is abused. The methadone helps prevent the euphoria and at the same time decreases the craving that is central to addiction. A typical dose that may work is 30-60 milligrams of methadone daily but this is variable and depends on the intensity of addiction among other factors. Alcohol rehab often involves an acute hospital based detoxification where a thorough medical assessment is done and then drugs belonging to the class called benzodiazepines are given to prevent withdrawal. Medical issues are often the main reason an addict enters a treatment entry point.



After this acute phase an outpatient 12 step program such as Alcoholics Anonymous is critical to maintain abstinence. Many patients who are addicted to drugs have co-morbid psychiatric conditions like depression that need to be addressed. Others have HIV/AIDS, which also need to be managed if a lasting solution is needed. Many rehab programs are covered by insurance and charity. They also have social workers who will help with the practical aspects of getting back to a productive life.



Above all, the commitment of the individuals working in the program helps sustain and develop faith and trust in the system since addicts are often marginalized members of society.




Drug Rehab provides detailed information on Drug Rehab, Drug Rehab Programs, Drug Rehab Centers, Drug And Alcohol Rehab and more. Drug Rehab is affiliated with Drug Detox Rehab.



Article Source: http://EzineArticles.com/?expert=Ken_Marlborough
http://EzineArticles.com/?Drug-and-Alcohol-Rehab&id=231119









Drug Treatment Outcome Study Specific links

Drug Treatment Outcome Study News

Guest Post: Data, Drugs, And Deception-- A True Story - Forbes


Guest Post: Data, Drugs, And Deception-- A True Story
Forbes
Actual true story: the conclusions of this study are neither novel nor valid. The Lancet meta-analysis, authored by the Cholesterol Treatment Trialists group, examines individual patient data from 27 statin studies. Their findings disagree with an ...

Read more...


Mixed results for mobile stroke treatment - Pocklington Post


Mixed results for mobile stroke treatment
Pocklington Post
Since (in the case of most strokes) the earlier treatment is given the better the outcome, this study is important. However, the study was not designed to find out if mobile stroke units improve important outcomes such as the long-term outlook for ...

Read more...


XenoPort Submits Investigational New Drug Application for XP23829 as a ... - MarketWatch (press release)


XenoPort Submits Investigational New Drug Application for XP23829 as a ...
MarketWatch (press release)
... announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to begin clinical studies of XP23829 as a potential treatment for relapsing-remitting multiple sclerosis (RRMS).

and more »

Read more...


Is Excessive Daytime Sleepiness the Cause of Learning and Behavior Problems in ... - Huffington Post (blog)


Is Excessive Daytime Sleepiness the Cause of Learning and Behavior Problems in ...
Huffington Post (blog)
For months now, I have been writing about the studies that are being published -- seemingly by the month -- linking obstructive sleep apnea (OSA) to more and more medical conditions, including hypertension, heart disease, mood and memory problems.

Read more...


Texas Researchers Studying Breast Cancer Prevention, Minorities and More ... - MarketWatch (press release)


Texas Researchers Studying Breast Cancer Prevention, Minorities and More ...
MarketWatch (press release)
... in new research dollars to develop breakthrough drugs for common breast cancers, more effectively treat advanced forms of the disease, and improve breast cancer outcomes for Latinas, with 2012 research funding from Susan G. Komen for the Cure(R).

and more »

Read more...


REG-Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for ... - Reuters


REG-Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for ...
Reuters
Summit Corporation plc ('Summit' or 'the Company') Summit Announces Initiation of Phase 1 Trial for the Treatment of Duchenne Muscular Dystrophy Oxford, UK, May 25 th , 2012, Summit (AIM: SUMM), a UK drug discovery company, today announced that it has ...
Summit Corporation PLC : Summit Announces Initiation of Phase 1 Trial for the ...PipelineReview.com (press release)

all 12 news articles »

Read more...


FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits ... - MarketWatch (press release)


FREEDOM Study Data: Patients Experience Sustained Quality of Life Benefits ...
MarketWatch (press release)
... today announced the latest interim findings from its FREEDOM (Following Rehabilitation, Economics and Everyday-Dialysis Outcome Measurements) Study, which found daily home hemodialysis treatments with the NxStage System One(TM) are associated with ...

and more »

Read more...


Topical Drug May Hit the Spot for Female Arousal - MedPage Today


Topical Drug May Hit the Spot for Female Arousal
MedPage Today
Women who used alprostadil (Femprox) cream had as much as 63% improvement in the primary outcome of satisfactory sexual encounters, as defined by responses to a validated sexuality questionnaire. Younger women (<45) treated with the highest ...

and more »

Read more...


Developing new drugs to treat diabetes - Medical Xpress


Developing new drugs to treat diabetes
Medical Xpress
Drucker studies gastrointestinal hormones and is internationally-renowned for research breakthroughs that have led to a new class of drugs for the treatment of type 2 diabetes. In past instalments of this series we've looked at the role of diet and ...

and more »

Read more...


XenoPort Submits Investigational New Drug Application for XP23829 as a ... - EON: Enhanced Online News (press release)


XenoPort Submits Investigational New Drug Application for XP23829 as a ...
EON: Enhanced Online News (press release)
(EON: Enhanced Online News)--XenoPort, Inc. (Nasdaq:XNPT) announced today that it has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) to begin clinical studies of XP23829 as a potential treatment for ...

and more »

Read more...